Related Experiment Video
Updated: Jun 30, 2026
11:17
Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
[Growth hormone usage in Prader-Willi syndrome]
1Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, SP, Brazil. durvald@iconet.com.br
Arquivos Brasileiros De Endocrinologia E Metabologia
|September 18, 2008
Summary
Prader-Willi syndrome (PWS) is a genetic disorder causing hypotonia and later hyperphagia leading to obesity. Growth hormone therapy (hrGH) can improve PWS patient outcomes but requires careful respiratory monitoring.
Area of Science:
- Genetics
- Endocrinology
- Pediatrics
Context:
- Prader-Willi syndrome (PWS) affects 1 in 60,000, caused by loss of paternal chromosome 15.
- PWS presents with severe hypotonia in infancy, followed by hyperphagia and obesity around age four.
- This leads to life-threatening complications including inanition and alveolar hypoventilation.
Purpose:
- To investigate the role and safety of growth hormone therapy (hrGH) in Prader-Willi syndrome patients.
- To assess the impact of hrGH on body composition, physical activity, and height in PWS.
- To highlight critical safety considerations for initiating hrGH treatment in PWS.
Summary:
- hrGH treatment aims to improve body composition and physical activity in PWS patients.
- Many PWS individuals have growth hormone deficiency, and hrGH can improve height standard deviation scores.
- Initiating hrGH requires mandatory evaluation of sleep apnea and airway examination due to potential respiratory compromise.
Impact:
- Optimizing hrGH therapy can enhance quality of life for individuals with Prader-Willi syndrome.
- Early identification of growth hormone deficiency and appropriate treatment can mitigate PWS-related growth issues.
- Vigilant respiratory monitoring during hrGH treatment is crucial for patient safety and preventing adverse events.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:27Major Hormones and Their Functions
Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
01:26Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:10Nature and Nurture
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
01:26Cellular Adaptation III: Hyperplasia
Hyperplasia is an increase in the number of cells in a tissue or organ due to enhanced cell division. It is an adaptive, controlled response to stimuli such as injury, hormones, or stress, involving mitosis to produce genetically identical cells and support tissue repair and regeneration.Tissue CapacityCertain tissues, including the epidermis, intestinal epithelium, bone marrow, and fibroblasts, have a high potential for hyperplasia. Others, such as bone, cartilage, and smooth muscle, show...